Source/Disclosures
Disclosures: The National Key Research and Development Program of China, National Natural Science Foundation of China, Key Basic Research grants from the Science and Technology Commission of Shanghai Municipality, International S&T Cooperation Program of China, Shanghai Municipal Science and Technology Major Project program, International Science and Technology Cooperation Program of China, and 111 Project grants supported this study. Singlera Genomics provided funding for the DNA methylation assay. Zhang is co-founder, equity holder and paid consultant of Singlera Genomics. Please see the study for all other authors’ relevant financial disclosures.
September 03, 2020
2 min read
Save

Blood test detects common cancer types 4 years before current screening methods

Source/Disclosures
Disclosures: The National Key Research and Development Program of China, National Natural Science Foundation of China, Key Basic Research grants from the Science and Technology Commission of Shanghai Municipality, International S&T Cooperation Program of China, Shanghai Municipal Science and Technology Major Project program, International Science and Technology Cooperation Program of China, and 111 Project grants supported this study. Singlera Genomics provided funding for the DNA methylation assay. Zhang is co-founder, equity holder and paid consultant of Singlera Genomics. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A novel blood-based assay demonstrated the ability to detect five cancer types up to 4 years earlier than current screening methods, according to study results published in Nature Communications.

The noninvasive PanSeer test (Singlera Genomics), which is based on DNA methylation, detected stomach, esophageal, colorectal, lung and liver cancer in 91% of asymptomatic individuals who were diagnosed with cancer 1 to 4 years later using standard detection methods.

A novel blood-based assay demonstrated the ability to detect five cancer types up to 4 years earlier than current screening methods.

Although the test may not predict which individuals go on to develop cancer, it could identify individuals who have cancerous growths but remain asymptomatic, according to the researchers.

“The ultimate goal would be performing blood tests like this routinely during annual health checkups,” Kun Zhang, PhD, professor and chair of the department of bioengineering at the University of California, San Diego, said in a press release. “But the immediate focus is to test people at higher risk, based on family history, age or other known risk factors.”

The Taizhou Longitudinal Study— a 10-year longitudinal study conducted between 2007 and 2017 in China — included 123,115 healthy individuals aged 25 to 90 years who provided plasma samples for long-term storage and were monitored for cancer by regular checkups with physicians. More than 1.6 million specimens have been gathered and archived.

For the current study, researchers analyzed plasma samples of 605 asymptomatic individuals, of whom 191 were diagnosed with stomach, esophageal, colorectal, lung or liver cancer up to 4 years after plasma collection. Investigators also tested samples of 223 patients with cancer, in addition to 200 primary tumor and normal tissue samples.

With a specificity of 96% (95% CI, 93-98), the test detected cancer accurately in 88% (95% CI, 80-93) of post-diagnosis samples.

Moreover, it detected cancer in 95% (95% CI, 89-98) of asymptomatic individuals who were later diagnosed with cancer, although researchers noted that this result needs to be confirmed in larger studies.

“The PanSeer assay provides a preliminary demonstration of early detection of multiple cancer types 4 years prior to conventional diagnosis in a robust manner, and lays the foundation for a noninvasive blood test for early detection of cancer in a high-risk (or average-risk in the future) population,” the researchers wrote. “[Although] much of current research is focused on developing new therapeutics, studies have shown that early detection has the potential to reduce both treatment cost and mortality rates from cancer by a significant amount.”

The five cancer types included in this study account for 261,530 annual U.S. cancer deaths and 2.1 million annual cancer deaths in China. Early detection could significantly decrease deaths due to these cancer types, the researchers added.

“Recent studies have also identified that early detection of cancer could reduce cancer treatment costs by $26 billion annually,” they wrote. “In the future, to fully establish the clinical utility of PanSeer and fully validate the results of pre-diagnostic detection of cancer, we hope to proceed with a large prospective study of healthy individuals to determine if noninvasive cancer screening can reduce cancer deaths in a cost-effective manner.”